SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Amendment No. 1)
*
Under the Securities Exchange Act of
1934
ESSA Pharma Inc.
(Name of Issuer
- as specified in its charter)
Common Shares
(Title
of Class of Securities)
29668H708
(CUSIP
Number)
Peter J. Luiso, Esq.
Chief Compliance Officer and General Counsel
Eventide Asset Management, LLC
One International Place, Suite 4210
Boston, Massachusetts 02110
(877) 771- 3836
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)
June 30, 2019
(Date of Event
which Requires Filing of this Statement)
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because
of Rule 13d-1(e)(f) or (g), check the following box
¨
.
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder
of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
1
|
NAME OF REPORTING PERSON
Eventide Asset Management, LLC
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
¨
(a)
¨
(b)
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS
OO
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
1,385,168
|
8
|
SHARED VOTING POWER
0
|
9
|
SOLE DISPOSITIVE POWER
1,385,168
|
10
|
SHARED DISPOSITIVE POWER
0
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,385,168
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
¨
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
17.4%
|
14
|
TYPE OF REPORTING PERSON
IA
|
|
|
|
|
1
|
NAME OF REPORTING PERSON
Finny Kuruvilla, M.D. Ph.D.
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
¨
(a)
¨
(b)
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS
OO
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
8
|
SHARED VOTING POWER
1,385,168
|
9
|
SOLE DISPOSITIVE POWER
0
|
10
|
SHARED DISPOSITIVE POWER
1,385,168
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,385,168
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
¨
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
17.4%
|
14
|
TYPE OF REPORTING PERSON
IN;HC
|
|
|
|
|
1
|
NAME OF REPORTING PERSON
Eventide Healthcare & Life Sciences Fund
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
¨
(a)
¨
(b)
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS
OO
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Ohio
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
8
|
SHARED VOTING POWER
766,522
|
9
|
SOLE DISPOSITIVE POWER
0
|
10
|
SHARED DISPOSITIVE POWER
766,522
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
766,522
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
¨
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.6%
|
14
|
TYPE OF REPORTING PERSON
IV
|
|
|
|
|
1
|
NAME OF REPORTING PERSON
Eventide Gilead Fund
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
¨
(a)
¨
(b)
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS
OO
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Ohio
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
8
|
SHARED VOTING POWER
618,646
|
9
|
SOLE DISPOSITIVE POWER
0
|
10
|
SHARED DISPOSITIVE POWER
618,646
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
618,646
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
¨
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.8%
|
14
|
TYPE OF REPORTING PERSON
IV
|
|
|
|
|
This Amendment No. 1 to
the Statement on Schedule 13D amends the initial Statement on Schedule 13D filed by the Reporting Persons (as defined below) as
filed on May 23, 2019 with respect to the Issuer (as defined below) in order to reflect certain amendments to the Reporting Persons’
ownership of Shares of the Issuer as reported herein.
Item 1.
Security and Issuer.
This Amendment No.
1 to the Statement on Schedule 13D relates to the Common Shares (the “Shares”) of ESSA Pharma Inc. (the “Issuer”).
The address of the principal executive offices of the Issuer is Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada,
V5Z 1K5.
Item 2.
Identity and Background.
This Amendment No.
1 to the Statement on Schedule 13D is being jointly filed by: (i) Eventide Asset Management, LLC, a Delaware limited liability
company registered as an investment adviser with the U.S. Securities and Exchange Commission (“Eventide”); (ii) Finny
Kuruvilla, M.D., Ph.D., a United States citizen who is a Managing Partner and a control person of Eventide (“Kuruvilla”);
(iii) Eventide Healthcare & Life Sciences Fund (the “Healthcare & Life Sciences Fund”), a separate investment
series of Mutual Fund Series Trust (the “Trust”), an investment company registered with the U.S. Securities and Exchange
Commission under the Investment Company Act of 1940, as amended, for which Eventide serves as investment adviser; and (iv) Eventide
Gilead Fund (the “Gilead Fund”), a separate investment series of the Trust for which Eventide also serves as investment
adviser. (Eventide, Kuruvilla, the Healthcare & Life Sciences Fund and the Gilead Fund are sometimes also referred to herein
individually as a "Reporting Person" and collectively as the "Reporting Persons". The Healthcare & Life
Sciences Fund and the Gilead Fund are sometimes referred to collectively as the “Funds”). Further information regarding
the identity and background of certain of the Reporting Persons is set forth in Exhibit B which is attached hereto.
During the last five years,
none of the Reporting Persons, nor, to the best knowledge of the Reporting Persons, any of their respective executive officers,
their respective managing members or any persons controlling their respective managing members has: (1) been convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors) or (2) been party to a civil proceeding of a judicial or administrative
body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation
with respect to such laws.
Item 3.
Source and Amount
of Funds or Other Consideration.
The Shares herein
reported as being beneficially owned by the Reporting Persons were acquired by Eventide directly acting solely on behalf of its
investment advisory clients. Eventide has purchased a total of 481,971 Shares in negotiated purchases and converted 904,000 warrants
(the “Warrants”) for an aggregate consideration of $13,158,230 (exclusive of brokerage commissions). To the best knowledge
of the Reporting Persons, the funds used in such purchases were from Eventide’s existing and available investment capital
and none of the consideration for such Shares was represented by borrowed funds.
Item 4.
Purpose of Transaction.
The Reporting Persons have
acquired the Shares for investment purposes and will continue to analyze their investment in the Issuer on an ongoing basis. As
part of this investment analysis process, the Reporting Persons have engaged in discussions with management of the Issuer and the
Reporting Persons reserve
the right to engage with third parties that may have an interest in the business affairs of the Issuer
in order to monitor their investment and consider possible strategic alternatives.
Effective as of May 14, 2019,
the Healthcare & Life Sciences Fund and the Gilead Fund each entered into a Waiver and Agreement to Exercise with the Issuer
with respect to the Warrants (the “Exercise Agreement”) pursuant to which the parties agreed to certain matters regarding
the terms of the exercise of the Warrants in connection with the Issuer’s proposed transaction with Realm Therapeutics plc
(the “Realm Transaction”). The Healthcare & Life Sciences Fund and the Gilead Fund each agreed to exercise the
Warrants subject to the conditions provided for in the Exercise Agreement, including certain conditions with respect to the timing
of the approval of the Realm Transaction. Effective as of June 30, 2019, the Funds exercised the Warrants in accordance with the
terms of the Exercise Agreement. The Exercise Agreement is incorporated herein by reference to Exhibit C included with the Reporting
Persons’ initial Statement on Schedule 13D as filed on May 23, 2019.
Depending upon such discussions
and consideration of strategic alternatives, the Reporting Persons could support one or more of the actions described in subparagraphs
(a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve the right to formulate other purposes, plans or proposals
regarding the Issuer to the extent deemed advisable by the Reporting Persons in light of current market conditions generally and
specifically as they relate to the Issuer. The Reporting Persons further reserve the right to add to or reduce their holdings in
the Issuer at any time as circumstances warrant without prior notice.
Item 5. Interest in Securities of
the Issuer.
Based on the most recently
available information from the Issuer, there are 7,963,628 Shares currently outstanding. As of June 30, 2019, the Reporting Persons
collectively may be deemed to beneficially own 1,385,168 Shares, which represents 17.4% of the outstanding Shares. The number of
Shares which may be deemed to be beneficially owned by the Reporting Persons are as follows:
Shares Deemed to be
Beneficially Owned By:
|
Nature of
Ownership
|
Percentage
of Class
|
(A)
Eventide
:
|
|
|
1,385,168
|
Sole Voting and Sole Dispositive Power (1)
|
17.4%
|
(B)
Kuruvilla:
|
|
|
1,385,168
|
Shared Voting and Shared Dispositive Power (2)
|
17.4%
|
(C)
Healthcare & Life
Sciences Fund
:
|
|
|
766,522
|
Shared Voting and Shared Dispositive Power (3)
|
9.6%
|
(D)
Gilead Fund
:
|
|
|
618,646
|
Shared Voting and Shared Dispositive Power (4)
|
7.8%
|
____________________
|
(1)
|
Such Shares are owned by investment advisory clients of Eventide. By reason of its investment advisory
relationship with such clients, Eventide is deemed to have sole voting and sole dispositive power over such Shares. The economic
interest in such Shares is held by such clients.
|
|
(2)
|
Because Kuruvilla is a Managing Partner and control person of Eventide, he could be deemed to share
the power to vote and dispose or direct the disposition of such Shares.
|
|
(3)
|
Such Shares are owned by the Healthcare & Life Sciences Fund. Because Eventide serves as investment
adviser to the Fund, the Fund may be deemed to share the power to vote and dispose or direct the disposition of such shares.
|
|
(4)
|
Such Shares are owned by the Gilead Fund. Because Eventide serves as investment adviser to the
Fund, the Fund may be deemed to share the power to vote and dispose or direct the disposition of such shares.
|
TRANSACTIONS
Information regarding
transactions in the Shares that have been effected by the Reporting Persons since the filing of the Reporting Persons’ initial
Statement on Schedule 13D as filed on May 23, 2019, are included in Exhibit D attached hereto.
Item 7.
Materials Filed
as Exhibits.
The following exhibits
are attached hereto:
Exhibit
A - Joint Filing Agreement of the Reporting Persons
Exhibit
B - Executive Officers and Control Persons of the Reporting Persons
Exhibit C
- Waiver and Agreement to Exercise – incorporated herein by reference to Exhibit C included with the Reporting Persons’
initial Statement on Schedule 13D as filed on May 23, 2019.
Exhibit D
- Transactions in Securities of the Issuer Since the Filing of the Reporting Persons’ Most Recent Statement on Schedule 13D.
In accordance
with Rule 13d-4 of the Securities Exchange Act of 1934, the Reporting Persons expressly disclaim the beneficial ownership of the
securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that
they are the beneficial owners of such securities.
SIGNATURES
The undersigned
certify, after reasonable inquiry and to the best knowledge and belief of the undersigned, that the information set forth in this
Amendment No. 1 to the Statement on Schedule 13D is true, complete and correct. The undersigned agree to the filing of this single
Amendment No. 1 to the Statement on Schedule 13D.
Eventide Asset Management, LLC*
Date: July 12, 2019
By: /s/ Peter J. Luiso
Name: Peter J. Luiso
Title: Chief Compliance Officer
and General Counsel
Finny Kuruvilla, M.D., Ph. D.*
Date: July 12, 2019
By: /s/ Finny Kuruvilla, M.D., Ph. D.
Name: Finny Kuruvilla, M.D., Ph. D.
Mutual Fund Series Trust, on behalf of
Eventide Healthcare & Life Sciences Fund*
Date: July 12, 2019
By: /s/ Jennifer A. Bailey
Name: Jennifer A. Bailey
Title: Secretary
Mutual Fund Series Trust, on behalf of
Eventide Gilead Fund*
Date: July 12, 2019
By: /s/ Jennifer A. Bailey
Name: Jennifer A. Bailey
Title: Secretary
* The Reporting Persons disclaim beneficial
ownership in the shares represented herein except to the extent of their pecuniary interest therein.
EXHIBIT A
Joint Filing Agreement Among
Eventide Asset Management, LLC, Finny Kuruvilla,
M.D., Ph.D.,
Mutual Fund Series Trust, on behalf of Eventide
Healthcare & Life Sciences Fund and Eventide Gilead Fund
WHEREAS
, in accordance with Rule 13d-1(k)(1)
under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to
be filed whenever one or more persons are required to file such a statement or any amendments thereto pursuant to Section 13(d)
of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto
is filed on behalf of each of them:
NOW, THEREFORE
, the parties hereto agree
as follows:
Eventide Asset Management, LLC, Finny Kuruvilla,
M.D., Ph. D., and Mutual Fund Series Trust, on behalf of the Eventide Healthcare & Life Sciences Fund and the Eventide Gilead
Fund, do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file an Amendment No. 1 to the Statement on Schedule
13D relating to their ownership of the Common Shares of the Issuer, and do hereby further agree that said Amendment No. 1 to the
Statement on Schedule 13D shall be filed on behalf of each of them.
Eventide Asset Management, LLC
Date: July 12, 2019
By: /s/ Peter J. Luiso
Name: Peter J. Luiso
Title: Chief Compliance Officer and
General Counsel
Finny Kuruvilla, M.D., Ph.D.
Date: July 12, 2019
By: /s/ Finny Kuruvilla, M.D., Ph.
D.
Name: Finny Kuruvilla
Mutual Fund Series Trust, on behalf of
Eventide Healthcare & Life Sciences Fund
Date: July 12, 2019
By: /s/ Jennifer A. Bailey
Name: Jennifer A. Bailey
Title: Secretary
Mutual Fund Series Trust, on behalf of
Eventide Gilead Fund
Date: July 12, 2019
By: /s/ Jennifer A. Bailey
Name: Jennifer A. Bailey
Title: Secretary
EXHIBIT B
OFFICERS AND CONTROL PERSONS OF THE REPORTING
PERSONS
Except where otherwise noted, each of the individuals
named below is a citizen of the United States with a principal business address as indicated below.
A. Eventide Asset Management, LLC
Eventide Asset
Management, LLC is an investment adviser registered with the U.S. Securities and Exchange Commission and organized as a limited
liability company under the laws of the State of Delaware. Its address is:
One International Place, Suite 4210
Boston, Massachusetts 02110
The officers of
Eventide Asset Management, LLC are:
Name
Title
Robin C. John Chief Executive Officer
Finny Kuruvilla, M.D., Ph. D.
*
Chief Investment
Officer
Peter J. Luiso, Esq. Chief Compliance Officer and General
Counsel
*
Mr.
Kuruvilla is deemed to be a control person of Eventide Asset Management, LLC as a result of his ownership interest in the firm.
B. Mutual Fund Series Trust, on behalf of each of Eventide Healthcare
& Life Sciences Fund and Eventide Gilead Fund
Mutual Fund
Series Trust is an investment company organized as a business trust under the laws of the State of Ohio and it is registered with
the U.S. Securities and Exchange Commission. The Eventide Healthcare & Life Sciences Fund and the Eventide Gilead Fund are
each separate investment series of the Trust and share Officers and Trustees with the Trust. Its address is:
17605 Wright Street
Omaha, Nebraska 68130
Information
regarding the Trustees and Officers of Mutual Fund Series Trust is incorporated herein by reference to the Section titled “Trustees
and Officers” in the Statement of Additional Information included in Post-Effective Amendment No. 403 to the Registration
Statement on Form N-1A of the Trust as filed with the U.S. Securities and Exchange Commission on June 4, 2019.
EXHIBIT D
TRANSACTIONS
IN SECURITIES OF THE ISSUER SINCE THE FILING OF THE REPORTING PERSONS’ MOST RECENT STATEMENT ON SCHEDULE 13D
No transactions in the Shares
have been effected by the Reporting Persons or to the best knowledge of the Reporting Persons, by any executive officer, director,
managing member, affiliate or subsidiary of any of the Reporting Persons since the filing of the Reporting Persons’ initial
Statement on Schedule 13D on May 23, 2019, except the following transactions:
Reporting
Person
|
Transaction
|
Date
|
No. of
Shares
*
|
Average Price Per
Share
*
|
The Funds
|
Exercise of Warrants
|
6/30/19
|
903,198
|
$2.25
|
________________
*
Effective as of June 30, 2019, the Funds completed
the cashless exercise of 904,000 pre-funded Warrants of the Issuer pursuant to the terms of the Exercise Agreement resulting in
903,198 Shares issued to the Funds.
25870320.3.BUSINESS
ESSA Pharma (NASDAQ:EPIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ESSA Pharma (NASDAQ:EPIX)
Historical Stock Chart
From Apr 2023 to Apr 2024